Compare Honeywell Aerospace Inc. Common Stock (HONA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell Aerospace Inc. Common Stock vs Summit Therapeutics Inc — how do they compare? Honeywell Aerospace Inc. Common Stock trades at $156.54 (market cap $50.14B), while Summit Therapeutics Inc trades at $15.03 (market cap $12.38B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 4.1× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell Aerospace Inc. Common Stock for 0 Days and Summit Therapeutics Inc for 16 Days on average.
| HONA | SMMT | |
|---|---|---|
Market Cap | $50.14B | $12.38B |
Volume | 1,433,364 | 7,111,626 |
Sector | Industrials | Health |
52-Week High | $269.95 | $26.38 |
52-Week Low | $151.58 | $12.43 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $64.96B | $11.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today but remains volatile following recent positive developments. The stock shows a bullish technical signal with strong moving average support and neutral oscillators. Fundamentally, the company reports no revenue and significant losses (-$1.08B net income for 2025), but recent news includes a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, driving investor optimism.
The outlook is cautiously optimistic due to strong analyst support (65% buy ratings) and a $29.33 consensus price target, representing significant upside. Key risks include ongoing cash burn, lack of current revenue, and clinical trial execution. The AstraZeneca partnership provides substantial validation and funding, but investors should monitor upcoming Q3 2026 earnings and clinical milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell Aerospace Inc. Common Stock
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
